Caffeine ( DrugBank: Caffeine )

8 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
6	パーキンソン病	5
21	ミトコンドリア病	1
46	悪性関節リウマチ	3
78	下垂体前葉機能低下症	1
96	クローン病	1
97	潰瘍性大腸炎	1
265	脂肪萎縮症	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02655614 (ClinicalTrials.gov)	May 31, 2016	7/1/2016	A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis	A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: GDC-0134;Drug: Placebo;Drug: Rabeprazole;Drug: Midazolam;Drug: Caffeine	Genentech, Inc.	NULL	Completed	18 Years	N/A	All	54	Phase 1	United States;Canada;Netherlands

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03970798 (ClinicalTrials.gov)	May 22, 2019	23/5/2019	A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin	A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin	Parkinson's Disease	Drug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	44 Years	Male	50	Phase 1	Japan
2	JPRN-UMIN000022187	2016/05/06	06/05/2016	Research on Parkinson's disease pathogenesis based on analysis of caffeine absorption in patients with Parkinson's disease	Research on Parkinson's disease pathogenesis based on analysis of caffeine absorption in patients with Parkinson's disease - Analysis of caffeine absorption in patients with Parkinson's disease	Parkinson's disease	PD group, 200 mg caffeine administration, qd, 1 day Control group, 200 mg caffeine administration, qd, 1 day	Department of Neurology, Juntendo University	NULL	Complete: follow-up complete	40years-old	60years-old	Male and Female	20	Not applicable	Japan
3	NCT01738178 (ClinicalTrials.gov)	April 2014	28/11/2012	Caffeine as a Therapy for Parkinson's Disease	Caffeine as a Therapeutic Agent in Parkinson's Disease	Parkinson's Disease	Drug: Caffeine;Drug: Placebo	McGill University Health Center	Pontifícia Universidade Católica do Paraná;University of Calgary;University of Newfoundland and Eastern Health;University Health Network, Toronto;UBC Hospital;Movement Disorder Clinic - Deer Lodge Centre;The Ottawa Hospital	Completed	45 Years	75 Years	All	119	Phase 3	Brazil;Canada
4	NCT01190735 (ClinicalTrials.gov)	August 2010	26/8/2010	Caffeine for Motor Manifestations of Parkinson's Disease	Caffeine for Motor Manifestations of Parkinson's Disease: An Open-Label Dose-Response Study.	Parkinson's Disease	Drug: Caffeine alkaloid	Ron Postuma	Canadian Institutes of Health Research (CIHR)	Completed	18 Years	N/A	Both	28	Phase 2	Canada
5	NCT00459420 (ClinicalTrials.gov)	April 2007	11/4/2007	Caffeine for Excessive Daytime Somnolence in Parkinson's Disease	Caffeine for Excessive Daytime Somnolence in Parkinson's Disease	Parkinson's Disease;Excessive Daytime Somnolence	Drug: Caffeine 100-200 mg BID;Drug: placebo	Ron Postuma	Canadian Institutes of Health Research (CIHR);University of Toronto	Completed	18 Years	N/A	Both	58	Phase 2/Phase 3	Canada

先頭へ

21. ミトコンドリア病

臨床試験数 : 39 / 薬物数 : 42 - (DrugBank : 32) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04643249 (ClinicalTrials.gov)	November 10, 2020	13/11/2020	Drug-drug Interaction Study of KL1333 in Healthy Subjects	A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects	Mitochondrial Disease	Drug: KL1333;Drug: Flurbiprofen;Drug: Dextromethorphan;Drug: Bupropion;Drug: Midazolam injection;Drug: Omeprazole;Drug: Caffeine;Drug: Repaglinide	Abliva AB	NULL	Completed	18 Years	65 Years	All	14	Phase 1	United Kingdom

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04246762 (ClinicalTrials.gov)	April 6, 2021	27/1/2020	Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4	A Phase 1, Open-label, Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4	Rheumatoid Arthritis	Drug: Olokizumab;Drug: Omeprazole;Drug: Caffeine;Drug: Warfarin+ Vitamin K;Drug: Midazolam	R-Pharm International, LLC	IQVIA RDS Ireland Ltd;Thermo Fisher Scientific FS	Completed	18 Years	70 Years	All	16	Phase 1	Bulgaria;Moldova, Republic of
2	NCT03131973 (ClinicalTrials.gov)	May 13, 2017	25/4/2017	Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin	Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants	Rheumatoid Arthritis	Drug: BMS-986195;Drug: Methotrexate;Drug: Leucovorin;Drug: Caffeine;Drug: Montelukast;Drug: Flurbiprofen;Drug: Omeprazole;Drug: Midazolam;Drug: Digoxin;Drug: Pravastatin	Bristol-Myers Squibb	NULL	Completed	18 Years	50 Years	All	26	Phase 1	United States
3	NCT01636557 (ClinicalTrials.gov)	October 11, 2012	6/7/2012	A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis	A Phase I, Open-label, Drug Interaction Study to Evaluate the Effect of a Single-dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Sirukumab;Drug: Midazolam;Drug: Warfarin;Drug: Vitamin K;Drug: Omeprazole;Drug: Caffeine	Janssen Research & Development, LLC	NULL	Completed	18 Years	65 Years	All	12	Phase 1	Germany;Korea, Republic of;Moldova, Republic of;South Africa

78. 下垂体前葉機能低下症

臨床試験数 : 492 / 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00458991 (ClinicalTrials.gov)	June 2001	9/4/2007	rhGH Therapy on Hepatic Drug Metabolism	Recombinant Human Growth Hormone Therapy and Drug Metabolism	Growth Hormone Deficiency, Dwarfism	Drug: Dextromethorphan and Caffeine	University of Louisville	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	4 Years	14 Years	All	9	N/A	United States

96. クローン病

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02760615 (ClinicalTrials.gov)	November 1, 2016	2/5/2016	Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study	An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease	Colitis, Ulcerative;Crohn Disease	Drug: Caffeine;Drug: Losartan;Drug: Omeprazole;Drug: Dextromethorphan;Drug: Midazolam;Drug: Vedolizumab	Takeda	NULL	Withdrawn	18 Years	55 Years	All	0	Phase 4	United States

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02760615 (ClinicalTrials.gov)	November 1, 2016	2/5/2016	Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study	An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease	Colitis, Ulcerative;Crohn Disease	Drug: Caffeine;Drug: Losartan;Drug: Omeprazole;Drug: Dextromethorphan;Drug: Midazolam;Drug: Vedolizumab	Takeda	NULL	Withdrawn	18 Years	55 Years	All	0	Phase 4	United States

265. 脂肪萎縮症

臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04056000 (ClinicalTrials.gov)	September 1, 2019	23/5/2019	Lipodystrophy and Fat Metabolism During Exercise	The Regulation of Fat Metabolism in a Cyclist With Lipodystrophy: a Case Study	Healthy;Lipodystrophy, Familial Partial	Dietary Supplement: Caffeine;Dietary Supplement: High-carbohdyrate breakfast;Behavioral: 60-minutes of steady state exercise	University of Exeter	NULL	Withdrawn	18 Years	35 Years	Male	0	N/A	United Kingdom

先頭へ